Using AS1842856, an inhibitor of FoxO1 and (to a lesser extent) FoxO3 transcriptional activity [50], we confirmed that the expression of stem and progenitor cell markers in GBM-SCs, particularly that of Sox2, depends on the transcriptional activity of FoxO proteins (Figure 5D and 5I). The gene discussed is FOXO3; the disease is glioblastoma.